Guillaume Germain

Groupe d'analyse, ltee

H指数:18

被引数:985

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

FF/UMEC/VI and BUD/GLY/FORM in Patients with COPD Stepping Up from Dual Therapy Stratified by Exacerbations and Prior Dual Therapy: A Subgroup Analysis of a Comparative Effectiveness Study

Advances in Therapy

IF4

2026-01-190

OAAI

Economic impact of using cariprazine as the first versus subsequent adjunctive therapy for Medicaid beneficiaries with major depressive disorder

使用卡立派嗪作为 Medicaid 受益人中重度抑郁症患者的一线与二线附加治疗的经济影响

JOURNAL OF MEDICAL ECONOMICS

IF3

2025-12-310

PRE

Real-World Health Care Resource Utilization and Costs Among Patients with Activated Phosphoinositide 3-Kinase Delta (PI3Kδ) Syndrome in the United States

美国活化磷脂酰肌醇3-激酶δ(PI3Kδ)综合征患者的实际医疗资源利用及费用

Advances in Therapy

IF4

2025-10-080

Comparative Effectiveness of FF/UMEC/VI and BUD/GLY/FORM in Patients with COPD Stepping Up From Dual Therapy

比较FF/UMEC/VI与BUD/GLY/FORM在从双重疗法升级治疗的COPD患者中的疗效

Advances in Therapy

IF4

2025-07-070

Health care resource utilization and costs associated with switching versus augmenting antidepressant monotherapy in second-line treatment of major depressive disorder

重度抑郁症二线治疗中，与加量相比切换抗抑郁药单药治疗相关的医疗资源利用及成本

Journal of Affective Disorders

IF4.9

2025-07-020

Healthcare resource utilization and costs of using cariprazine as the first versus subsequent adjunctive therapy for major depressive disorder

重度抑郁症患者使用卡利拉赞作为初始与后续增效剂治疗时的医疗资源利用及成本

JOURNAL OF MEDICAL ECONOMICS

IF3

2025-02-010

Impact of cariprazine on body weight and blood pressure among adults with bipolar I disorder, schizophrenia, or major depressive disorder in a real-world setting

general psychiatry

IF3.1

2025-01-270

OAAI

Comparative Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol and Budesonide/Glycopyrrolate/Formoterol Fumarate among US Patients with Chronic Obstructive Pulmonary Disease

ADVANCES IN THERAPY

IF4

2024-12-280

OAAI

Adherence and Persistence with Single-Inhaler Triple Therapy Among Patients with COPD Using Commercial and Medicare Advantage US Health Plan Claims Data

ADVANCES IN THERAPY

IF4

2024-12-051

OAAI

Pre-Exposure Prophylaxis for the Prevention of HIV-1: An Assessment of Oral Pre-Exposure Prophylaxis Usage Patterns, First Evidence of HIV-1, and HIV-1 Risk Factors in the United States

暴露前预防预防HIV-1: 对美国口服暴露前预防使用模式，HIV-1的第一证据和HIV-1危险因素的评估

AIDS PATIENT CARE AND STDS

IF3.8

2024-11-010

PRE

Fluticasone Furoate/Umeclidinium/Vilanterol Initiation Following a COPD Exacerbation: Benefits of Prompt Initiation on COPD Outcomes

ADVANCES IN THERAPY

IF4

2024-10-250

OAAI

Belantamab mafodotin monotherapy for relapsed or refractory multiple myeloma: a real-world observational study in the United States

HAEMATOLOGICA

IF7.9

2024-10-170

OAAI

Evaluating the real-world effectiveness of belimumab in patients with SLE using SLE-related laboratory values and rheumatoid arthritis-derived disease activity measures: RAPID3, swollen joint count and tender joint count

LUPUS SCIENCE & MEDICINE

IF3.5

2024-04-030

OAAI

Real-World Study of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol on Asthma Control in the US

JOURNAL OF ASTHMA AND ALLERGY

IF3

2023-12-016

OAAI

Impact of Cariprazine on Weight and Blood Pressure in Bipolar I Depression: A Real-World Study Using Electronic Medical Records

CNS SPECTRUMS

IF4.1

2023-04-140

Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Non-valvular Atrial Fibrillation (NVAF) Patients with Diabetes in a US Population

ADVANCES IN THERAPY

IF4

2023-01-193

OAAI

The real-world health resource use and costs of misdiagnosing bipolar I disorder

JOURNAL OF AFFECTIVE DISORDERS

IF4.9

2022-11-014

OAAI

Impact of adherence to treatment with inhaled corticosteroids/long-acting β-agonists on asthma outcomes in the United States

therapeutic advances in musculoskeletal disease

IF3

2022-08-299

OAAI

Adherence and persistence to once-daily single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in the USA: A real-world study

RESPIRATORY MEDICINE

IF3.1

2022-06-0134

OAAI

Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the USA

TARGETED ONCOLOGY

IF4

2020-12-072

OAAI

Guillaume Germain

个人简介

教育背景

工作经历

荣誉奖项

研究方向